[{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dapsone","moa":"Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MSIDS Research Foundation \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-absorbable Film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elutia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Not Applicable"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Bio-film","sponsorNew":"Citius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Rifampicin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

                          Brand Name : CanGaroo RM

                          Molecule Type : Small molecule

                          Upfront Cash : $35.0 million

                          November 09, 2023

                          Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Berkeley Biologics

                          Deal Size : $35.0 million

                          Deal Type : Divestment

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.

                          Brand Name : CanGaroo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 19, 2023

                          Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : HighCape Capital

                          Deal Size : $26.2 million

                          Deal Type : Private Placement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...

                          Brand Name : CanGaroo

                          Molecule Type : Small molecule

                          Upfront Cash : $35.0 million

                          September 18, 2023

                          Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Berkeley Biologics

                          Deal Size : $35.0 million

                          Deal Type : Divestment

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Citius intends to use the net proceeds for pre-clinical and clinical development of its product candidates, including Mino-Wrap, a malleable, bio-absorbable film impregnated with minocycline and rifampin used in patients that elect to undergo reconstruct...

                          Brand Name : Mino-Wrap

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 04, 2023

                          Lead Product(s) : Minocycline Hydrochloride,Rifampicin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : H.C. Wainwright & Co.

                          Deal Size : $15.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : CanGaroo RM Antibacterial Envelope contains the antibiotics rifampin and minocycline, which have been shown in preclinical testing to reduce bacterial colonization on the envelope.

                          Brand Name : CanGaroo

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 20, 2023

                          Lead Product(s) : Rifampicin,Minocycline Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander infections following breast reconstructive surgeries. Some next steps for Mino-Wrap development include designing and executing a large animal study...

                          Brand Name : Mino-Wrap

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 09, 2020

                          Lead Product(s) : Minocycline Hydrochloride,Rifampicin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          MSIDS Research Foundation

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          MSIDS Research Foundation

                          Country arrow
                          2024 ACI Convention
                          Not Confirmed

                          Details : Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 28, 2020

                          Lead Product(s) : Dapsone,Doxycycline,Rifampicin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Mino-Wrap is a novel approach to reducing post-operative infections associated with surgical implants. Mino-Wrap is a liquefying gel-based wrap containing minocycline and rifampin for reducing tissue expander (TE) infections following breast reconstructi...

                          Brand Name : Mino-Wrap

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 04, 2020

                          Lead Product(s) : Minocycline Hydrochloride,Rifampicin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank